Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer
Aileen I. Fernandez(Yale University), David L. Rimm(Yale University), Robert A. Anders(Johns Hopkins University), Mikhail Lisovsky(Dartmouth–Hitchcock Medical Center), Zongming Eric Chen(Mayo Clinic), Zhaohai Yang(University of Pennsylvania), Yvonne G. Y. Chan, Jodi Weidler, Andrew M. Bellizzi(University of Iowa), Purva Gopal, Charles T. Robbins(Yale University), Leena McCann, Jinru Shia(Memorial Sloan Kettering Cancer Center), Diana Agostini‐Vulaj(University of Rochester Medical Center), Wei Chen(Fujian Medical University), Xiuli Liu(Guangxi Medical University), Lei Zhao(Union Hospital), Huamin Wang(The University of Texas MD Anderson Cancer Center), Xuchen Zhang(Qingdao University), Michael Bates, Patricia Gaule(Yale University)
Cited by 26
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k